Drug Class Detail

Drug Class PD-L1/PD-1 antibody

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PF-06801591 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 PF-06801591 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
unspecified PD-1 antibody Experimental PD-1 antibody PD-L1/PD-1 antibody 48
Cemiplimab Libtayo REGN2810|SAR439684 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation (FDA.gov).
CS1001 WBP3155 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CS1001 (WBP3155) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).
XmAb20717 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 XmAb20717 is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
BI 754091 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BI 754091 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).
HLX20 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 HLX20 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
GLS-010 AB122 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 GLS-010 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (FDA.gov).
HLX10 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 HLX10 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).
MGD013 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 PD-L1/PD-1 antibody 48 MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217).
AK104 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AK104 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
BMS-936559 MDX-1105 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BMS-936559 is a PD-1 (PDCD1) human monoclonal antibody, which blocks the binding of PD-L1 (CD274) resulting in a T-cell mediated immune response and possible tumor regression (PMID: 22658128).
Camrelizumab SHR-1210|INCSHR-1210 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502).
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer (FDA.gov).
CX-072 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CX-072 is a prodrug consisting of a monoclonal antibody to PD-L1 (CD274) and a masking peptide that is cleaved by proteases specific to tumor cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3072-3072).
MEDI0680 AMP-514 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MEDI0680 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
FAZ053 FAZ-053|FAZ 053 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 FAZ053, is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
unspecified PD-L1 antibody Experimental PD-L1 antibody PD-L1/PD-1 antibody 48
LY3300054 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 LY3300054, is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568).
AMP-224 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AMP-224 is a fusion protein comprised of the extracellular domain of PD-L2 (PDCD1LG2) and the Fc region of IgG1, which binds to the PD-1 (PDCD1) receptor thereby potentially resulting in restoration of the T-cell mediated immune response (NCI Drug Dictionary).
AGEN2034 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AGEN2034 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086).
ABBV-181 ABBV181|ABBV 181 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 ABBV-181 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
PDR001 Spartalizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
KN035 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 KN035 is a nanobody that targets PD-L1 (CD274) and prevents interaction with PD-1 (PDCD1), potentially resulting in decreased tumor growth (PMID: 28280600).
TSR-042 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 TSR-042 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310).
JTX-4014 JTX4014 PD-L1/PD-1 antibody 48 JTX-4014 is a monoclonal antibody that targets PD-1, potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary).
Pembrolizumab Keytruda MK-3475 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
BCD-100 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BCD-100 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29300693).
Avelumab Bavencio MSB0010718C Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in patients with metastatic Merkel cell carcinoma and urothelial carcinoma (FDA.gov).
JS001 JS-001|TAB001 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 JS001 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).
BGB-A333 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BGB-A333 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
AK105 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AK105 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
Sintilimab Tyvyt IBI308 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038).
BGB-A317 Tislelizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (NCI Drug Dictionary).
M7824 MSB0011359C Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 TGFBR2 Antibody 2 M7824 is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798).
LZM009 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 LZM009 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
MSB2311 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MSB2311 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
MGA012 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MGA012 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl, TPS2601).
CX-188 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Limited information is currently available on CX-188, a putative PD-1 probody (Dec 2018).
GB226 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 GB226 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
FS118 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 PD-L1/PD-1 antibody 48 FS118 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
CS1003 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CS1003 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
Pidilizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Pidilizumab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
Sym021 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822).
CA-170 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CA-170 is a small molecule inhibitor of PD-L1 (CD274) and V-domain Ig suppressor of T-cell activation (VISTA), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD).
JNJ-63723283 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 JNJ-63723283 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093).
Molecular Profile Protein Effect Treatment Approaches